Fibrin sealant - Grifols

Drug Profile

Fibrin sealant - Grifols

Alternative Names: FS Grifols; Human fibrinogen / human thrombin - Grifols; VeraSeal

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Grifols
  • Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Fibrinogen replacements; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Surgical blood loss

Most Recent Events

  • 16 Mar 2018 Grifols Therapeutics plans a phase III trial for Surgical blood loss (Adjunctive treatment, In infants, In children, In adolescents) in March 2018 (NCT03461406)
  • 14 Sep 2017 European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommends approval of fibrin sealant for Surgical blood loss in European Union
  • 13 Sep 2017 Preregistration for Surgical blood loss in European Union (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top